Clinical Trials Logo

Overactive Bladder clinical trials

View clinical trials related to Overactive Bladder.

Filter by:

NCT ID: NCT02657057 Completed - Overactive Bladder Clinical Trials

Effects of Transcutaneous and Percutaneous PTNS on Idiopathic OAB

Start date: November 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if Transcutaneous Tibial Nerve Stimulation (TENS) is as effective as Percutaneous Tibial Nerve Stimulation (PTNS) as therapeutic option for subjects with Idiopathic Overactive Bladder (OAB) who have failed conventional therapy.

NCT ID: NCT02656173 Completed - Overactive Bladder Clinical Trials

A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)

Start date: January 25, 2016
Phase: Phase 4
Study type: Interventional

The primary objective of the study was to investigate the efficacy of mirabegron versus placebo in male patients with OAB symptoms while taking the alpha blocker, tamsulosin, for BPH.

NCT ID: NCT02622555 Completed - Overactive Bladder Clinical Trials

Cardiovascular Morbidity During Treatment of Overactive Bladder With B3 Agonists

Start date: August 2013
Phase: Phase 4
Study type: Observational

Overactive bladder syndrome complicates life for many women. 60-70% of women report improvement with treatment but the antikolinergic treatment is often limited by the adverse events, for example dry mouth, obstipation and urinary retention. Mirabegron is a b3-adrenoreceptor agonist which induces detrusor relaxation. Earlier studies has demonstrated similar efficacy comparing Mirabegron with antimuscarinics but a significant reduction of adverse events. The aim of the present study is to survey cardiovascular adverse events with Mirabegron treatment in a general population suffering from overactive bladder syndrome.

NCT ID: NCT02620410 Completed - Overactive Bladder Clinical Trials

Treatment of REfractory Overactive BLadder With the AXonics Sacral Neuromodulation System (RELAX-OAB)

RELAX-OAB
Start date: June 2016
Phase: N/A
Study type: Interventional

The RELAX-OAB (Treatment of REfractory Overactive BLadder with the AXonics Sacral Neuromodulation System) is a post-market clinical follow-up (PMCF) study designed to confirm the performance of the Axonics Sacral Neuromodulation (SNM) System as an aid in the treatment of the symptoms of overactive bladder (OAB) as well as capturing patient satisfaction and quality of life data.

NCT ID: NCT02614482 Completed - Overactive Bladder Clinical Trials

Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children.

FOXY2015
Start date: October 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long term tolerability of Fesoterodine and its efficacy for overactive bladder syndrome in children.

NCT ID: NCT02601287 Completed - Clinical trials for Urinary Incontinence

A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients

Start date: November 2015
Phase: Phase 4
Study type: Interventional

This is a safety and efficacy study of BOTOX® (Botulinum Toxin Type A) in the Treatment of Adult Korean Patients with Urinary Incontinence due to Neurogenic Detrusor Overactivity or Overactive Bladder.

NCT ID: NCT02600715 Completed - Overactive Bladder Clinical Trials

Reduction of Bladder Injection Pain With Belladonna Opiate Suppository

ROBIN
Start date: November 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study is to test whether using belladonna & opiate suppositories (B&Os) can improve patient discomfort during Onabotulinumtoxin A (BoNT) injection into the bladder for treatment of overactive bladder, neurogenic detrusor overactivity, or interstitial cystitis.

NCT ID: NCT02590250 Completed - Clinical trials for Urinary Incontinence

A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in India

Start date: December 16, 2015
Phase:
Study type: Observational

This is a Post-Marketing Surveillance study in India to evaluate safety and efficacy of BOTOX® (Botulinum Toxin Type A) in the treatment of patients with urinary incontinence due to neurogenic detrusor overactivity or overactive bladder.

NCT ID: NCT02583529 Recruiting - Parkinson Disease Clinical Trials

Neurogenic Overactive Bladder Treatment on Parkinson's Disease Through Back Tibial Nerve Electrostimulation

NOVTPD
Start date: July 2014
Phase: Phase 0
Study type: Interventional

Dysfunctions of the lower urinary tract are non-motor symptoms common engines in Parkinson's disease (PD). Urodynamic changes in PD include overactive bladder (OB), characterized by urgency with or without urge incontinence , usually with frequency and nocturia . The aim of this study is to evaluate the efficacy and effectiveness of the treatment of OB in patients with PD with the use of a specific treatment: Posterior Tibial Nerve Electrostimulation (PTNE).

NCT ID: NCT02570035 Completed - Clinical trials for Cardiovascular Disease

Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease

Start date: December 2012
Phase: N/A
Study type: Observational

This purpose of this study is to investigate the effects of mirabegron on the cardiovascular system in patients with overactive bladder with current or a history of cardiovascular disease.